Who is Not a CXL Candidate?
Since crosslinking (CXL) was approved by the FDA in 2016, many individuals with KC have been encouraged to consider this treatment. While doctors are quick to point out that CXL is not a cure, in the majority of instances, disease progression halts and the resulting vision is no worse than it is on the day of surgery. For those who fear a lifetime of ongoing vision impairment, CXL is a welcome relief. Dr. Annie Nguyen MD , cornea specialist and Assistant Professor at the USC/Roski Eye Institute, has seen the value of CXL to her patients.
However, she notes, not everyone benefits from CXL.
Click the link to read more: Who is Not a CXL Candidate
Life With KC
The National Keratoconus Foundation (NKCF) is an outreach program of The Gavin Herbert Eye Institute, UC Irvine.
The NKCF is dedicated to increasing the awareness and understanding of keratoconus and the support of scientific research into the cause and treatment of keratoconus.